Clinical relevance of tumour-associated macrophages

MJ Pittet, O Michielin, D Migliorini - Nature reviews Clinical oncology, 2022‏ - nature.com
In the past decade, substantial advances have been made in understanding the biology of
tumour-associated macrophages (TAMs), and their clinical relevance is emerging. A …

[HTML][HTML] The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF

S Ghalehbandi, J Yuzugulen, MZI Pranjol… - European journal of …, 2023‏ - Elsevier
Angiogenesis is a double-edged sword; it is a mechanism that defines the boundary
between health and disease. In spite of its central role in physiological homeostasis, it …

CXCL12-CXCR4/CXCR7 axis in cancer: from mechanisms to clinical applications

Y Yang, J Li, W Lei, H Wang, Y Ni, Y Liu… - … journal of biological …, 2023‏ - pmc.ncbi.nlm.nih.gov
Cancer is a multi-step disease caused by the accumulation of genetic mutations and/or
epigenetic changes, and is the biggest challenge around the world. Cytokines, including …

B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity

CM Laumont, BH Nelson - Cancer Cell, 2023‏ - cell.com
Our understanding of tumor-infiltrating lymphocytes (TILs) is rapidly expanding beyond T cell-
centric perspectives to include B cells and plasma cells, collectively referred to as TIL-Bs. In …

The chemokine receptor CXCR4 in cell proliferation and tissue regeneration

ME Bianchi, R Mezzapelle - Frontiers in Immunology, 2020‏ - frontiersin.org
The CXCR4 receptor upon binding its ligands triggers multiple signaling pathways that
orchestrate cell migration, hematopoiesis and cell homing, and retention in the bone …

Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade

S Srivastava, SN Furlan, CA Jaeger-Ruckstuhl… - Cancer cell, 2021‏ - cell.com
Adoptive therapy using chimeric antigen receptor-modified T cells (CAR-T cells) is effective
in hematologic but not epithelial malignancies, which cause the greatest mortality. In breast …

Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy

SH Kiaie, H Salehi-Shadkami, MJ Sanaei… - Journal of …, 2023‏ - Springer
Immune checkpoint (ICP) molecules expressed on tumor cells can suppress immune
responses against tumors. ICP therapy promotes anti-tumor immune responses by targeting …

mTORC1 and mTORC2 in cancer and the tumor microenvironment

LC Kim, RS Cook, J Chen - Oncogene, 2017‏ - nature.com
The mammalian target of rapamycin (mTOR) is a crucial signaling node that integrates
environmental cues to regulate cell survival, proliferation and metabolism, and is often …

The progress and promise of RNA medicine─ an arsenal of targeted treatments

JM Sasso, BJB Ambrose, R Tenchov… - Journal of medicinal …, 2022‏ - ACS Publications
In the past decade, there has been a shift in research, clinical development, and commercial
activity to exploit the many physiological roles of RNA for use in medicine. With the rapid …

The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies

SK Daniel, YD Seo, VG Pillarisetty - Seminars in cancer biology, 2020‏ - Elsevier
Single agent checkpoint inhibitor therapy has not been effective for most gastrointestinal
solid tumors, but combination therapy with drugs targeting additional immunosuppressive …